DICTrank: The largest reference list of 1318 human drugs ranked by risk of drug-induced cardiotoxicity using FDA labeling

Drug Discov Today. 2023 Nov;28(11):103770. doi: 10.1016/j.drudis.2023.103770. Epub 2023 Sep 13.

Abstract

Drug-induced cardiotoxicity (DICT) is a leading cause of drug trial failure and discontinuation. Current drug annotations for cardiotoxicity largely focus on individual outcomes or mechanisms. Considering the broad spectrum of adverse cardiac events, we developed Drug-Induced Cardiotoxicity Rank (DICTrank) using FDA labeling and comprehensively classified 1318 human drugs into four categories: Most-DICT-Concern (n = 341), Less-DICT-Concern (n = 528), No-DICT-Concern (n = 343), and Ambiguous-DICT-Concern (n = 106). Notably, DICTrank covers diverse therapeutic categories, of which several were enriched with Most-DICT-Concern drugs, such as antineoplastic agents, sex hormones, anti-inflammatory drugs, beta-blockers, and cardiac therapy. DICTrank currently presents the largest drug list of DICT annotation, and it could contribute to the development of new approach methods, including AI models for early identification of DICT risk during drug development and beyond.

Keywords: FDA label; cardiotoxicity; drug annotation; drug safety; new approach methods; risk assessment.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / toxicity
  • Cardiotoxicity* / etiology
  • Humans

Substances

  • Antineoplastic Agents